NASDAQ:OPNT - Opiant Pharmaceuticals News Headlines

Sign in or create an account to add this stock to your watchlist.
$21.06 -0.78 (-3.57 %)
(As of 09/24/2018 04:00 PM ET)
Previous Close$21.84
Today's Range$21.06 - $21.84
52-Week Range$12.75 - $48.00
Volume629 shs
Average Volume102,250 shs
Market Capitalization$61.65 million
P/E Ratio7.34
Dividend YieldN/A
Beta-0.13

Headlines

Opiant Pharmaceuticals (NASDAQ OPNT) News Headlines

Source:
DateHeadline
Opiant Pharmaceuticals Announces Proposed Public Offering of Common StockOpiant Pharmaceuticals Announces Proposed Public Offering of Common Stock
finance.yahoo.com - September 24 at 4:54 PM
Opiant nabs BARDA funding up to $4.6M for opioid overdose med; shares up 7% after hoursOpiant nabs BARDA funding up to $4.6M for opioid overdose med; shares up 7% after hours
seekingalpha.com - September 21 at 8:30 AM
Opiant Pharmaceuticals Announces Contract with Biomedical Advanced Research and Development Authority for Up to $4.6 Million to Accelerate Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid OverdoseOpiant Pharmaceuticals Announces Contract with Biomedical Advanced Research and Development Authority for Up to $4.6 Million to Accelerate Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose
finance.yahoo.com - September 20 at 4:51 PM
How Should You Think About Opiant Pharmaceuticals Inc’s (NASDAQ:OPNT) Risks?How Should You Think About Opiant Pharmaceuticals Inc’s (NASDAQ:OPNT) Risks?
finance.yahoo.com - September 14 at 4:55 PM
Opnet Technologies, Inc. (OPNT) Reports Manufacturing Pact with Consort Medical Plc for OPNT003Opnet Technologies, Inc. (OPNT) Reports Manufacturing Pact with Consort Medical Plc for OPNT003
www.streetinsider.com - September 12 at 8:26 AM
Zacks: Brokerages Set $44.50 Price Target for Opiant Pharmaceuticals Inc (OPNT)Zacks: Brokerages Set $44.50 Price Target for Opiant Pharmaceuticals Inc (OPNT)
www.americanbankingnews.com - September 11 at 10:31 AM
Opiant Pharmaceuticals signs manufacturing agreement with Consort Medical for OPNT003 for treatment of opioid overdoseOpiant Pharmaceuticals signs manufacturing agreement with Consort Medical for OPNT003 for treatment of opioid overdose
seekingalpha.com - September 10 at 4:52 PM
Opiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid OverdoseOpiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
finance.yahoo.com - September 10 at 8:30 AM
Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia NervosaOpiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia Nervosa
globenewswire.com - September 5 at 8:32 AM
UPDATE: Opiant Pharmaceuticals, Inc. (OPNT) Reports Final Patient Enrolled in Phase 2 Clinical Trial Evaluating ...UPDATE: Opiant Pharmaceuticals, Inc. (OPNT) Reports Final Patient Enrolled in Phase 2 Clinical Trial Evaluating ...
www.streetinsider.com - September 4 at 5:02 PM
Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia ...Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia ...
www.nasdaq.com - September 4 at 8:34 AM
Opiant Pharma up 73% premarket on EBS takeout of Adapt PharmaOpiant Pharma up 73% premarket on EBS takeout of Adapt Pharma
seekingalpha.com - August 29 at 4:54 PM
OPNT: Adapt Pharma® Acquired for $650 Million…OPNT: Adapt Pharma® Acquired for $650 Million…
finance.yahoo.com - August 29 at 4:54 PM
Investor Expectations to Drive Momentum within Capital Senior Living, Thermon Group, L.B. Foster, Anavex Life Sciences, Opiant Pharmaceuticals, and Huron Consulting Group — Discovering Underlying Factors of InfluenceInvestor Expectations to Drive Momentum within Capital Senior Living, Thermon Group, L.B. Foster, Anavex Life Sciences, Opiant Pharmaceuticals, and Huron Consulting Group — Discovering Underlying Factors of Influence
finance.yahoo.com - August 16 at 8:31 AM
Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q2 2018 Results - Earnings Call TranscriptOpiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - August 15 at 8:32 AM
OPNT: Increasing Royalties from NARCAN® Nasal Spray…OPNT: Increasing Royalties from NARCAN® Nasal Spray…
finance.yahoo.com - August 10 at 5:16 PM
Opiant Pharmaceuticals, Inc. to Host Earnings CallOpiant Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - August 9 at 5:47 PM
Opiant Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results and Provides Corporate UpdateOpiant Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - August 9 at 5:47 PM
Opiant up 36% premarketOpiant up 36% premarket
seekingalpha.com - August 4 at 9:46 AM
Opiant Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on ...Opiant Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on ...
globenewswire.com - August 2 at 5:21 PM
Opiant Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on Thursday, August 9Opiant Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on Thursday, August 9
finance.yahoo.com - August 2 at 8:32 AM
Opiant Pharma up 20% premarketOpiant Pharma up 20% premarket
seekingalpha.com - July 12 at 4:42 PM
Opiant Pharmaceuticals Announces Receipt of First Tranche from National Institutes of Health Grant for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid OverdoseOpiant Pharmaceuticals Announces Receipt of First Tranche from National Institutes of Health Grant for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
finance.yahoo.com - June 25 at 5:27 PM
Opiant Pharmaceuticals to Participate in Opioid Panel at the BIO International ConventionOpiant Pharmaceuticals to Participate in Opioid Panel at the BIO International Convention
finance.yahoo.com - June 4 at 5:05 PM
Opiant Pharmaceuticals to Participate in The American Society of Clinical Psychopharmacology 2018 Annual MeetingOpiant Pharmaceuticals to Participate in The American Society of Clinical Psychopharmacology 2018 Annual Meeting
finance.yahoo.com - May 29 at 8:32 AM
Report: Exploring Fundamental Drivers Behind Opiant Pharmaceuticals, American Railcar Industries, Omega Flex, Johnson Outdoors, Thermon Group, and Connecticut Water Service — New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Opiant Pharmaceuticals, American Railcar Industries, Omega Flex, Johnson Outdoors, Thermon Group, and Connecticut Water Service — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - May 25 at 8:27 AM
OPNT: KOL Event Highlights Medications for Addictions and Related DisordersOPNT: KOL Event Highlights Medications for Addictions and Related Disorders
finance.yahoo.com - May 15 at 5:41 PM
Opiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate UpdateOpiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 8 at 5:28 PM
Opiant Pharmaceuticals To Host Key Opinion Leader Meeting on Medications for Addictions and Related DisordersOpiant Pharmaceuticals To Host Key Opinion Leader Meeting on Medications for Addictions and Related Disorders
finance.yahoo.com - May 3 at 8:26 AM
Blog Exposure - Opiant Pharma Receives Grant for Development of OPNT003 for Treatment of Opioid OverdoseBlog Exposure - Opiant Pharma Receives Grant for Development of OPNT003 for Treatment of Opioid Overdose
finance.yahoo.com - April 20 at 8:36 AM
Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for ...Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for ...
globenewswire.com - April 19 at 8:26 AM
BRIEF-Opiant Pharmaceuticals Awarded Grant Of Approximately $7.4 Mln From The National Institutes Of HealthBRIEF-Opiant Pharmaceuticals Awarded Grant Of Approximately $7.4 Mln From The National Institutes Of Health
www.reuters.com - April 19 at 8:26 AM
Opiant awarded $7.4M NIH grant to support OPNT003 development; shares ahead 2% premarketOpiant awarded $7.4M NIH grant to support OPNT003 development; shares ahead 2% premarket
seekingalpha.com - April 18 at 5:37 PM
Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid OverdoseOpiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
finance.yahoo.com - April 18 at 8:26 AM
Will Opiant Pharma Solve The Biggest Crisis That The FDA Is Currently Facing?Will Opiant Pharma Solve The Biggest Crisis That The FDA Is Currently Facing?
seekingalpha.com - April 11 at 8:42 AM
Free Research Report as HubSpot’s Quarterly Earnings Surpassed Analysts’ EstimatesFree Research Report as HubSpot’s Quarterly Earnings Surpassed Analysts’ Estimates
finance.yahoo.com - March 22 at 8:38 AM
Trump says he is working to lower prescription drug pricesTrump says he is working to lower prescription drug prices
finance.yahoo.com - March 20 at 8:40 AM
As U.S. opioid crisis grows, Trump calls for death penalty for dealersAs U.S. opioid crisis grows, Trump calls for death penalty for dealers
finance.yahoo.com - March 20 at 8:40 AM
OPNT: Opiant Developing New Opioid Overdose TreatmentOPNT: Opiant Developing New Opioid Overdose Treatment
finance.yahoo.com - March 19 at 5:10 PM
Opiant Pharmaceuticals, Inc. to Present a Corporate Overview at the Oppenheimer 28th Annual Healthcare ConferenceOpiant Pharmaceuticals, Inc. to Present a Corporate Overview at the Oppenheimer 28th Annual Healthcare Conference
finance.yahoo.com - March 19 at 5:10 PM
Opiant Pharmaceuticals, Inc. Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides ... - GlobeNewswire (press release)Opiant Pharmaceuticals, Inc. Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides ... - GlobeNewswire (press release)
globenewswire.com - March 9 at 8:35 AM
Opiant Pharmaceuticals reports 5M resultsOpiant Pharmaceuticals reports 5M results
seekingalpha.com - March 7 at 6:23 PM
Opiant Pharmaceuticals, Inc. Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides Corporate UpdateOpiant Pharmaceuticals, Inc. Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides Corporate Update
finance.yahoo.com - March 7 at 6:23 PM
Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications - GlobeNewswire (press release)Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications - GlobeNewswire (press release)
globenewswire.com - February 22 at 8:30 AM
Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain MedicationsAegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications
finance.yahoo.com - February 22 at 8:30 AM
OPNT: Developing Longer-Acting Opioid Overdose TreatmentOPNT: Developing Longer-Acting Opioid Overdose Treatment
finance.yahoo.com - February 13 at 3:50 PM
Opnet Technologies, Inc. (OPNT) Reports ~$11.7M in Royalty & Milestone Payments Related to 2017 Sales of NARCANOpnet Technologies, Inc. (OPNT) Reports ~$11.7M in Royalty & Milestone Payments Related to 2017 Sales of NARCAN
www.streetinsider.com - February 9 at 9:48 AM
Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 ... - GlobeNewswire (press release)Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 ... - GlobeNewswire (press release)
globenewswire.com - February 8 at 8:18 AM
Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN® Nasal Spray for Opioid OverdoseOpiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN® Nasal Spray for Opioid Overdose
finance.yahoo.com - February 8 at 8:18 AM
Opiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding Warrants - GlobeNewswire (press release)Opiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding Warrants - GlobeNewswire (press release)
globenewswire.com - January 2 at 5:35 PM
This page was last updated on 9/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel